Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2008-1-14
pubmed:abstractText
Bone marrow (BM)-derived mesenchymal stem cells (MSCs) are multipotent, nonhemopoietic progenitors that also possess regulatory activity on immune effector cells through different mechanisms. We demonstrate that human BM-derived MSCs expressed high levels of Toll-like receptors (TLRs) 3 and 4, which are both functional, as shown by the ability of their ligands to induce nuclear factor kappaB (NF-kappaB) activity, as well as the production of interleukin (IL)-6, IL-8, and CXCL10. Of note, ligation of TLR3 and TLR4 on MSCs also inhibited the ability of these cells to suppress the proliferation of T cells, without influencing their immunophenotype or differentiation potential. The TLR triggering effects appeared to be related to the impairment of MSC signaling to Notch receptors in T cells. Indeed, MSCs expressed the Notch ligand Jagged-1, and TLR3 or TLR4 ligation resulted in its strong downregulation. Moreover, anti-Jagged-1 neutralizing antibody and N[N-(3,5-difluorophenacetyl-l-alanyl)]-S-phenylglycine t-butyl ester (DAPT), an inhibitor of Notch signaling, hampered the suppressive activity of MSCs on T-cell proliferation. These data suggest that TLR3 and TLR4 expression on MSCs may provide an effective mechanism to block the immunosuppressive activity of MSCs and therefore to restore an efficient T-cell response in the course of dangerous infections, such as those sustained by double-stranded RNA viruses or Gram-negative bacteria, respectively.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1549-4918
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
26
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
279-89
pubmed:meshHeading
pubmed-meshheading:17962701-Bone Marrow Cells, pubmed-meshheading:17962701-CD4-Positive T-Lymphocytes, pubmed-meshheading:17962701-Cell Differentiation, pubmed-meshheading:17962701-Cell Proliferation, pubmed-meshheading:17962701-Cells, Cultured, pubmed-meshheading:17962701-Chemokines, pubmed-meshheading:17962701-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:17962701-Flow Cytometry, pubmed-meshheading:17962701-Humans, pubmed-meshheading:17962701-Lymphocyte Activation, pubmed-meshheading:17962701-Mesenchymal Stem Cells, pubmed-meshheading:17962701-Microscopy, Confocal, pubmed-meshheading:17962701-Multipotent Stem Cells, pubmed-meshheading:17962701-Receptors, Notch, pubmed-meshheading:17962701-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:17962701-Signal Transduction, pubmed-meshheading:17962701-Toll-Like Receptor 3, pubmed-meshheading:17962701-Toll-Like Receptor 4
pubmed:year
2008
pubmed:articleTitle
Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling.
pubmed:affiliation
Excellence Center of the University of Florence De Novo Therapy, Florence, Italy.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't